Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors

@article{Kanagawa2015MethotrexateIO,
  title={Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors
},
  author={H. Kanagawa and R. Masuyama and M. Morita and Yuiko Sato and Y. Niki and Tami Kobayashi and E. Katsuyama and A. Fujie and Wu Hao and T. Tando and Ryuichi Watanabe and K. Miyamoto and H. Morioka and M. Matsumoto and Y. Toyama and H. Saya and T. Miyamoto},
  journal={Journal of Bone and Mineral Metabolism},
  year={2015},
  volume={34},
  pages={526-531}
}
The increasing number of osteoporosis patients is a pressing issue worldwide. Osteoporosis frequently causes fragility fractures, limiting activities of daily life and increasing mortality. Many osteoporosis patients take numerous medicines due to other health issues; thus, it would be preferable if a single medicine could ameliorate osteoporosis and other conditions. Here, we screened 96 randomly selected drugs targeting various diseases for their ability to inhibit differentiation of… Expand
Stat3 as a potential therapeutic target for rheumatoid arthritis
The Role of Ca2+-NFATc1 Signaling and Its Modulation on Osteoclastogenesis
...
1
2
...

References

SHOWING 1-10 OF 29 REFERENCES
Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation.
Osteoimmunology and the effects of the immune system on bone
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis
HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis
L-type Ca(2+) channel agonist inhibits RANKL-induced osteoclast formation via NFATc1 down-regulation.
Bone mass measurement and bone metabolism in rheumatoid arthritis: a review.
...
1
2
3
...